GlassScriptPhysician profile
Hannah Elizabeth Ray
NPI 1972287415
$1,445.04
in general payments reported to CMS, 2019-2025
21 companies · $1,111 in 2025
The $1,111 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $334 · 2025: $1,111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,445.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $462.74 | 2024-2025 | Uptravi, Opsumit, Opsynvi |
| Glaxosmithkline, LLC. | $189.38 | 2024-2025 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.60 | 2024-2025 | Ofev |
| Genzyme Corporation | $89.42 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $87.08 | 2024-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $77.49 | 2024-2025 | Tezspire, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $65.75 | 2025 | Glassia |
| Averitas Pharma INC. | $56.92 | 2025 | Qutenza |
| Corcept Therapeutics | $48.27 | 2025 | Korlym |
| Tandem Diabetes Care, INC. | $32.27 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Grifols USA, LLC | $28.05 | 2025 | Prolastin-C Liquid |
| Ascensia Diabetes Care US INC. | $26.57 | 2025 | |
| Mallinckrodt Hospital Products INC. | $25.86 | 2024 | Acthar |
| Medtronic, INC. | $24.57 | 2025 | Minimed 780g |
| Bioventus LLC | $23.33 | 2024 | Exogen Ultrasound Bone Healing System |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $22.34 | 2024 | Smartvest |
| Xeris Pharmaceuticals, INC. | $20.83 | 2025 | Gvoke Hypopen |
| Dexcom, INC. | $18.71 | 2025 | Dexcom G6 Transmitter |
| Ucb, INC. | $17.19 | 2025 | Bimzelx |
| Ascendis Pharma Endocrinology INC | $14.95 | 2025 | Yorvipath |
| Mylan Specialty L.P. | $14.72 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.